New York—February 4, 2014
ANRF grant recipients represent the top of a highly competitive field of young MD, PhD and MD-PhD scientists at nonprofit research institutions across the US. Applications are reviewed annually by ANRF's Scientific Advisory Board of world-renowned physician-scientists. From their list of deserving researchers, The Sontag Foundation conducts their own internal review to choose which scientist they will support.
“George embodies both an exemplary work ethic and the creative thinking necessary for breakthrough research," said Dr. Mary Crow, a member of the ANRF’s Scientific Advisory Board and Physician-in-Chief, Chair of the Division of Rheumatology, and Director of Rheumatology Research at Hospital for Special Surgery "We're thrilled that he's been recognized by the ANRF and The Sontag Foundation and look forward to the results of his research over the coming year."
Dr. Kalliolias added, “I am excited about continuing my work on the pathogenesis of Rheumatoid Arthritis with such robust support. I am honored to have been chosen as this year's Sontag Fellow and continue the good work of the researchers who have held this title before me." Former Sontag Fellows include top researchers from institutions around the country, such as Harvard Medical School, Johns Hopkins Medical Center and University of Michigan-Ann Arbor.
“The pioneering work of Dr. Kalliolias will provide a better understanding of the causes of rheumatoid arthritis which should lead to the development of more effective treatments. This made selecting him as the recipient of the Sontag Fellowship an easy choice,” said Rick Sontag, President of The Sontag Foundation.
Dr. Kalliolias has been involved in arthritis research since 2004. He is a physician-scientist trained in Internal Medicine and Rheumatology, with an expertise in Rheumatoid Arthritis and other immune-mediated rheumatic diseases. Dr. Kalliolias’ research is focused on inhibiting the joint destruction that is caused by inflammation in rheumatoid arthritis. Specifically, he is investigating the role of joint fibroblasts, important but little-studied players that represent a new and exciting potential therapeutic target for rheumatoid arthritis. He will be honored at a luncheon given at Hospital for Special Surgery in February.
About HSS | Hospital for Special Surgery
HSS is the world’s leading academic medical center focused on musculoskeletal health. At its core is Hospital for Special Surgery, nationally ranked No. 1 in orthopedics (for the ninth consecutive year) and No. 3 in rheumatology by U.S.News & World Report (2018-2019). Founded in 1863, the Hospital has one of the lowest infection rates in the country and was the first in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. The global standard total knee replacement was developed at HSS in 1969. An affiliate of Weill Cornell Medical College, HSS has a main campus in New York City and facilities in New Jersey, Connecticut and in the Long Island and Westchester County regions of New York State. In 2017 HSS provided care to 135,000 patients and performed more than 32,000 surgical procedures. People from all 50 U.S. states and 80 countries travelled to receive care at HSS. In addition to patient care, HSS leads the field in research, innovation and education. The HSS Research Institute comprises 20 laboratories and 300 staff members focused on leading the advancement of musculoskeletal health through prevention of degeneration, tissue repair and tissue regeneration. The HSS Global Innovation Institute was formed in 2016 to realize the potential of new drugs, therapeutics and devices. The culture of innovation is accelerating at HSS as 130 new idea submissions were made to the Global Innovation Institute in 2017 (almost 3x the submissions in 2015). The HSS Education Institute is the world’s leading provider of education on the topic on musculoskeletal health, with its online learning platform offering more than 600 courses to more than 21,000 medical professional members worldwide. Through HSS Global Ventures, the institution is collaborating with medical centers and other organizations to advance the quality and value of musculoskeletal care and to make world-class HSS care more widely accessible nationally and internationally.